Evidence map›Paper›PMID 27152197›Full record

ArticleBiomarker research2016

Evaluation of Caspase-9b and PP2Acα2 as potential biomarkers for chronic lymphocytic leukemia.

Leticia Domínguez-Berrocal, Xiguang Zhang, Jean Marc Zini, Jesús Fominaya, Angelita Rebollo, Jerónimo Bravo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomarker research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Leticia Domínguez-BerrocalInstituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Científicas (IBV-CSIC), c/ Jaime Roig 11, 46010 Valencia, Spain.
Xiguang ZhangInstitut National de la Santé et de la Recherche Médicale (INSERM), U1135, 83, Université Pierre et Marie Curie, 91 bd de l'Hôpital, 75013 Paris, France.
Jean Marc ZiniAssistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Saint Louis, 1 avenue Claude Vellefaux, 75010 Paris, France.
Jesús FominayaInstitut National de la Santé et de la Recherche Médicale (INSERM), U1135, 83, Université Pierre et Marie Curie, 91 bd de l'Hôpital, 75013 Paris, France.
Angelita RebolloInstitut National de la Santé et de la Recherche Médicale (INSERM), U1135, 83, Université Pierre et Marie Curie, 91 bd de l'Hôpital, 75013 Paris, France.
Jerónimo BravoInstituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Científicas (IBV-CSIC), c/ Jaime Roig 11, 46010 Valencia, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDisruption of alternative splicing in apoptotic factors has been associated to chronic lymphocytic leukemia among other cancers and hematological malignancies. The proapoptotic proteins Caspase-9 and PP2Acα are functionally related in a direct interaction, which constitutes a promising target for cancer therapy. Both proteins present aberrant mRNA splicing variants that are antiapoptotic (Caspase-9b) and catalytically inactive (PP2Acα2), respectively.

resultsIn this work we have analyzed the relative abundance of the aberrant spliced forms Caspase-9b and PP2Acα2 in several cell lines and chronic lymphocytic leukemia patients and correlated it with several parameters of the disease. Despite 40 % of the patients presented Caspase-9b dysregulation, there was no direct association between alterations in Caspase-9b relative abundance and the parameters analyzed in medical records. More importantly, PP2Acα2 dysregulation was observed in 88 % of CLL patients and was related with advanced stages of the malignancy.

conclusionsCaspase-9b dysregulation seemed to be associated with the disease, although the differences between healthy donors and CLL patients were not statistically significant. However, PP2Acα2 dysregulation was significantly different between healthy donors and CLL patients and correlated with Binet B and C stages; therefore, we propose the use of PP2Acα2 dysregulation as a potential biomarker for advanced stages of chronic lymphocytic leukemia.

Indexed as

Alternative splicingBiomarkerCaspase-9Caspase-9bChronic lymphocytic leukemiaPP2AcαPP2Acα2

Identifiers

PMID27152197
PMCPMC4857392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.